| Unique ID issued by UMIN | UMIN000063629 |
|---|---|
| Receipt number | R000072821 |
| Scientific Title | RAISE: Clinical Outcomes and Safety in Systemic Rheumatic Diseases Treated With Anti-inflammatory and Immunomodulatory Agents - A Multicenter Electronic Health Record-Derived Registry Study |
| Date of disclosure of the study information | 2026/11/16 |
| Last modified on | 2026/11/16 07:05:58 |
RAISE: Clinical Outcomes and Safety in Systemic Rheumatic Diseases Treated With Anti-inflammatory and Immunomodulatory Agents - A Multicenter Electronic Health Record-Derived Registry Study
RAISE
RAISE: Clinical Outcomes and Safety in Systemic Rheumatic Diseases Treated With Anti-inflammatory and Immunomodulatory Agents - A Multicenter Electronic Health Record-Derived Registry Study
RAISE
| Japan |
Systemic rheumatic diseases treated with anti-inflammatory and immunomodulatory agents
| Clinical immunology |
Others
NO
The aim of this study is to establish a multicenter registry using electronic health record data from patients with systemic rheumatic diseases and to continuously evaluate treatment patterns, clinical outcomes, and the safety of anti-inflammatory and immunomodulatory therapies in real-world clinical practice.
Safety,Efficacy
All-cause mortality and causes of death
Observational
| Not applicable |
| Not applicable |
Male and Female
Patients meeting all of the following criteria will be included in the analysis:
1. A history of outpatient visits to, or hospitalization under the primary or secondary care of, a rheumatology and connective tissue disease department at a participating institution.
2. A diagnosis of a systemic rheumatic disease, regardless of whether the relevant classification criteria are fulfilled.
3. Initiation of anti-inflammatory and immunomodulatory therapy for the purpose of controlling disease activity after the start of electronic health record operation at each participating institution.
Patients who meet either of the following criteria:
Patients who were not registered in this study and visited the study institution 15 or more days after initiation of anti-inflammatory or immunomodulatory treatment for disease activity control of systemic rheumatic diseases at another medical institution, and who meet either of the following conditions:
(a) Patients with no history of hospitalization in the Department of Rheumatology and Clinical Immunology (or equivalent department) at the study institution, and who had either three or fewer actual outpatient visit days in that department or an observation period of less than 100 days, with no occurrence of death or adverse events by the time of the last observation.
(b) Patients for whom the diagnostic evidence, date of treatment initiation, treatment details (including the history of anti-inflammatory or immunomodulatory drug use and the initial dose of glucocorticoids), or history of disease relapse cannot be confirmed from the provided medical records or other clinical information.
7500
| 1st name | Taio |
| Middle name | |
| Last name | Naniwa |
Nagoya City University Hospital
Department of Rheumatology and Clinical Immunology / Department of Respiratory Medicine, Immunology and Allergology, Graduate School of Medical Sciences
467-8602
1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan
052-853-8216
tnaniwa@med.nagoya-cu.ac.jp
| 1st name | Shinya |
| Middle name | |
| Last name | Tamechika |
Nagoya City University Hospital
Department of Rheumatology and Clinical Immunology / Department of Respiratory Medicine, Immunology
467-8602
1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan
052-853-8216
s-tame@med.nagoya-cu.ac.jp
Nagoya City University
None
Other
Nagoya City University Medical Research Institutional Review Board
1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan
052-853-8348
clinical_research@med.nagoya-cu.ac.jp
YES
60-26-0011
Nagoya City University Medical Research Institutional Review Board
| 2026 | Year | 11 | Month | 16 | Day |
Partially published
Open public recruiting
| 2026 | Year | 04 | Month | 14 | Day |
| 2026 | Year | 04 | Month | 24 | Day |
| 2026 | Year | 04 | Month | 24 | Day |
| 2036 | Year | 03 | Month | 31 | Day |
Eligible patients will be identified using existing electronic medical records at each participating institution. Clinical data will be collected from medical records, medication and laboratory orders, and test results. Text data from medical records will also be used when necessary. After registration, data on patient characteristics, disease activity, treatments, laboratory findings, organ damage, disease relapse, and adverse events will be updated periodically for longitudinal follow-up. Patients will be classified into cohorts according to treatment details and the timing of treatment initiation. Real-world treatment patterns, clinical outcomes, and safety will be analyzed. No study-specific interventions, additional examinations, or biological sample collection will be performed.
| 2026 | Year | 11 | Month | 14 | Day |
| 2026 | Year | 11 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072821